DOJ, SEC Reach Deal In Drug Maker's Insider-Trading

Law360, New York (March 9, 2007, 12:00 AM EST) -- Federal prosecutors and securities regulators have wrapped up parallel cases against a former executive at bankrupt generic drug maker Able Laboratories Inc., after accusing him of insider-trading in a scheme to conceal quality control deficiencies.

Former Able vice president Shashikant C. Shah pled guilty on March 8 to charges in a case filed by the U.S. Department of Justice, while simultaneously consenting to a deal with the U.S. Securities and Exchange Commission in New Jersey District Court.

Shah was Able's vice president of quality control, quality...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.